3beta,22,25-Trihydroxylanosta-8,23-diene | 106483-69-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3beta,22,25-Trihydroxylanosta-8,23-diene
• 英文别名: (E,6S)-6-[(3S,10S,13R,14R,17R)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-3-ene-2,5-diol
• CAS: 106483-69-6
• 化学式: C₃₀H₅₀O₃
• 分子量: 458.7
• InChiKey: KIWHRCNGJTUEHJ-YPDKNQGRSA-N

物化性质

• 沸点：
  561.8±50.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• TRITERPENOID-CONTAINING PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：ZHENG Qinyuan

  公开号：US20200384003A1

  公开（公告）日：2020-12-10

  The present invention relates to a novel use of a triterpenoid. In particular, the present invention provides a use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof in the preparation of a pharmaceutical composition or a preparation for preventing and/or treating ocular diseases caused by crystalline lens lesions. A novel finding of the present invention is that the compound of formula I can prevent and/or treat ocular diseases caused by crystalline lens lesions, such as prevention and treatment of cataracts, is safe, has low toxicity and few side effects, and has remarkable therapeutic efficacy and development and application prospects.